Categories: BrainNews

Neurogen Biomarking to present novel data on at-home p-tau 217 testing for Alzheimer’s disease at Alzheimer’s Association International Conference® 2025

CHICAGO, July 17, 2025 (GLOBE NEWSWIRE) — Neurogen Biomarking will present novel data on at-home p-tau 217 testing for Alzheimer’s disease at the upcoming Alzheimer’s Association International Conference® (AAIC) in Toronto, Canada. Chief Scientific Officer, Elisabeth Thijssen, PhD will report the results of a study designed to validate remote collection of blood biomarkers for Alzheimer’s disease and related disorders.

The Neurogen session is highlighted in AAIC’s Featured Research Session (FRS) that debut and discuss innovative and impactful research findings, drawing together multiple studies that share a common focus. AAIC has also designated Neurogen’s presentation a Clinical Pearl for its real-world relevance to dementia diagnosis and care.

Neurogen’s presentation details include:

  • Date/Time: Monday, July 28 at 2 p.m. EDT
  • Format: Podium presentation followed by Q&A
  • Scientific Session: Remote Collection of Blood Biomarkers for Alzheimer’s disease and related disorders
  • Presenter: Elisabeth Thijssen, PhD, Chief Scientific Officer Neurogen Biomarking
  • Location: Hall F

About Neurogen

Neurogen Biomarking is on a global mission to give everyone equitable access to brain health care. The company offers the first at-home blood biomarker test for phosphorylated (p-tau217) using proprietary blood collection technology and advanced digital cognitive testing with results guided by board-certified neurologists via telehealth. Neurogen’s vision is to deliver accessible technology, actionable insights, and pathways to precision-based proactive care to support early detection and care for Mild Cognitive Impairment (MCI) and dementia associated with Alzheimer’s disease (AD). Neurogen was founded by award-winning neurologist, Dr. Rany Aburashed and is guided by world-renowned brain health experts.

To learn more, visit www.neurogenbiomarking.com or follow us on LinkedIn.

Media Contact:

Reilly Connect for Neurogen Biomarking
Ashley.Biladeau@reillyconnect.com
952.994.4021

mia.joan@reillyconnect.com
872.240 3696

Staff

Recent Posts

Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options

Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…

6 hours ago

Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts

Telehealth Platform Facilitates Compounded Semaglutide and Tirzepatide Access Through Licensed Provider Evaluation as FDA Shortage…

6 hours ago

Best Peptides for Boosting Growth Hormone: ReadyRx Lists Prescription Sermorelin in Injectable and Needle-Free Formats for 2026

Analysis examines best peptides for boosting growth hormone as ReadyRx lists prescription sermorelin in injectable…

6 hours ago

Best Fat Burner For Men 2026: Effective Fat Burning Supplements For Men’s Belly Fat Launched By Wolfson Brands Ltd

Discover the best fat burner for men in 2025. Explore Wolfson Brand’s effective fat-burning supplements…

6 hours ago

MEDIROM Partners with World

Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex…

6 hours ago